Thursday, May 07, 2015 6:11:44 AM
Vancouver, BC -- May 6, 2015 - Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CSE: ATT), specialty biotechnology company with capabilities through its wholly-owned subsidiaries as a botanical drug development company that develops and licenses natural health products, medicines, extractions and ingredients for the biologics, nutraceutical, bioceutical and cosmetic markets -- some of which will contain cannabinoid compounds, today announced that Brazos Minshew, former Chief Science Officer of TriVita, Inc., former Chief Executive Officer of Therapy Alternatives and Director of Marketing for Tiena Health, will assume the role of Chief Science Officer ("CSO") of Abattis Bioceuticals Corp. effective April 20, 2015.
Brazos has been consulting for the Company since July 2014 and the Company is pleased to see him assume a larger role. Brazos commented, "By strengthening our scientific base, we look to obtain a leadership position for Abattis in deployment of innovative and breakthrough nutrition products that will improve human health for many years to come."
http://www.abattis.com/s/news.asp?ReportID=706666
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM